Awad A
CNS Drugs. 2018; 33(1):1-8.
PMID: 30511350
DOI: 10.1007/s40263-018-0588-3.
Chevalier A, Ntala E, Fung C, Priebe S, Bird V
PLoS One. 2018; 13(9):e0203457.
PMID: 30180196
PMC: 6122813.
DOI: 10.1371/journal.pone.0203457.
Sajatovic M, DiBiasi F, Legacy S
Neuropsychiatr Dis Treat. 2017; 13:2285-2296.
PMID: 28919760
PMC: 5587149.
DOI: 10.2147/NDT.S139557.
Xiao L, Gao Y, Zhang L, Chen P, Sun X, Tang S
Qual Life Res. 2016; 25(11):2825-2832.
PMID: 27216939
DOI: 10.1007/s11136-016-1319-1.
Gopalakrishnan R, Behere R, Sharma P
Indian J Psychol Med. 2015; 37(4):423-8.
PMID: 26702175
PMC: 4676209.
DOI: 10.4103/0253-7176.168585.
A history of health-related quality of life outcomes in psychiatry.
Revicki D, Kleinman L, Cella D
Dialogues Clin Neurosci. 2014; 16(2):127-35.
PMID: 25152652
PMC: 4140507.
Can we trust the internet to measure psychotic symptoms?.
Moritz S, Van Quaquebeke N, Lincoln T, Kother U, Andreou C
Schizophr Res Treatment. 2013; 2013:457010.
PMID: 23936652
PMC: 3725883.
DOI: 10.1155/2013/457010.
Differences in levels of disability and quality of life between genders in schizophrenia remission.
Kujur N, Kumar R, Verma A
Ind Psychiatry J. 2011; 19(1):50-4.
PMID: 21694792
PMC: 3105560.
DOI: 10.4103/0972-6748.77638.
Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents.
Chengappa N, Parepally H, Brar J, Gopalani A, Chalasani L, Bear J
Indian J Psychiatry. 2011; 45(3):151-4.
PMID: 21206845
PMC: 2952159.
The clinical applicability of the Self-Appraisal of Illness Questionnaire (SAIQ) to chronic schizophrenic patients in Taiwan.
Kao Y, Liu Y
Psychiatr Q. 2010; 81(3):215-25.
PMID: 20364323
DOI: 10.1007/s11126-010-9131-5.
Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.
Kuroda N, Sun S, Lin C, Morita N, Kashiwase H, Yang F
Environ Health Prev Med. 2009; 13(5):288-95.
PMID: 19568916
PMC: 2698253.
DOI: 10.1007/s12199-008-0043-z.
Quality of life among bipolar disorder patients misdiagnosed with major depressive disorder.
Awad A, Rajagopalan K, Bolge S, McDonnell D
Prim Care Companion J Clin Psychiatry. 2007; 9(3):195-202.
PMID: 17632652
PMC: 1911165.
DOI: 10.4088/pcc.v09n0305.
Lack of insight in schizophrenia: impact on treatment adherence.
Buckley P, Wirshing D, Bhushan P, Pierre J, Resnick S, Wirshing W
CNS Drugs. 2007; 21(2):129-41.
PMID: 17284095
DOI: 10.2165/00023210-200721020-00004.
The impact of subjective well-being under neuroleptic treatment on compliance and remission.
de Millas W, Lambert M, Naber D
Dialogues Clin Neurosci. 2006; 8(1):131-6.
PMID: 16640124
PMC: 3181761.
How antipsychotics work-from receptors to reality.
Kapur S, Agid O, Mizrahi R, Li M
NeuroRx. 2006; 3(1):10-21.
PMID: 16490410
PMC: 3593357.
DOI: 10.1016/j.nurx.2005.12.003.
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder.
Hofer A, Rettenbacher M, Widschwendter C, Kemmler G, Hummer M, Fleischhacker W
Eur Arch Psychiatry Clin Neurosci. 2005; 256(4):246-55.
PMID: 16311896
DOI: 10.1007/s00406-005-0633-3.
The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial.
Kilian R, Angermeyer M
Qual Life Res. 2005; 14(5):1275-89.
PMID: 16047503
DOI: 10.1007/s11136-004-5533-x.
Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.
Lambert M, Naber D
CNS Drugs. 2004; 18 Suppl 2:5-17.
PMID: 15461312
DOI: 10.2165/00023210-200418002-00002.
Neuroleptic dysphoria: towards a new synthesis.
Voruganti L, Awad A
Psychopharmacology (Berl). 2003; 171(2):121-32.
PMID: 14647964
DOI: 10.1007/s00213-003-1648-y.
Patients' subjective experiences of antipsychotics: clinical relevance.
Hellewell J
CNS Drugs. 2002; 16(7):457-71.
PMID: 12056921
DOI: 10.2165/00023210-200216070-00003.